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1. Introduction
   Infertility is a medical problem that affects more than 
80 million people worldwide and it is one of the indicators 
of poor reproductive health. It affects about 15% of global 
young adults’ population. It is a threat to humans continued 
survival on earth[1]. In sub-Saharan Africa, the male factor 
infertility is on the increase. In easthern and southern parts 
of Nigeria, the oligospermia and azoospermia have been 
identified as the common causes of male factor infertility, 
which are attributable partly to bacterial infections[2]. 
Seminal fluid infection has been implicated to contribute 
tremendously in the reduction of sperm density and cause 
abnormal sperm morphology. According to WHO, infection 
should be suspected in sperm pH changes and Nwakyoma 
et al. in their study stated that pH changes affect most of 
the seminal fluid parameters and that these contribute to 
the problem of infertility[3]. Meanwhile, Staphylococcus 
aureus, Streptococcus and Escherichia coli (E. coli) are 
among other causative microbes named both in Nigeria 
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and other parts of the globe[2]. The presence of DNA from 
sexually transmitted disease pathogens detected in semen 
of asymptomatic men seeking an infertility investigation 
is a further proof of microbes’ involvement in male factor 
infertility[1]. In reality, infertility is a multifactorial condition 
with more than one factor contributing to elicit the disease. 
The factors include psychological, emotional disorders, 
alcohol and drugs addiction that cause infertility in form of 
loss of libido, rapid ejaculation or erectile dysfunction. Some 
lifestyle and organic diseases such as smoking, obesity, 
diabetes, hypertension, cardiovascular and neurological 
disorders have been implicated to cause male infertility that 
manifest in form of oligospermia or azoospermia[4].
   Male factor infertility due to infections is often reversible. 
Most people who had acute epididymitis experienced 
temporary impairment of spermatogenesis that can be 
reversed with potent antibiotic therapy to normalcy[2]. 
Pefloxacin is a synthetic antimicrobial agent. It is the third 
generation of fluoroquinolones with a broad spectrum of 
activity against most Gram-negative and Gram-positive 
bacteria. Fluoroquinolones including ciprofloxacin and 
nalidixic acids can be used successfully in a variety of 
specific infections like urinary tract infections (UTIs)[5,6]. 
Pefloxacin has a good absorption with high bioavailability, a 
long half-life, excellent tissue and body fluid penetration[5,7]. 
   Infertility in males manifests as poor libido, low sperm 
count or poor sperm quality that necessitates the use of 
polyherbal formulation like Manix®[8]. This polyherbal 
formulation is commonly prescribed for Nigerian males with 
low sperm count and poor sperm quality by physicians. It 
has been established that Manix® reverses the age related 
decrease in testosterone levels in males to as much as 85% 
when taken for 90 d.  It also increases by 41% and improves 
sperm motility by 124%, and increases the sperm count four 
times in 90 d[8,9]. Each Manix® capsule contains extract 
(Manix® Product leaflet) of Asparagus racemosus, Tribulus 
terrestris, Tinospora cordifolia, Semecarpus anacardium, 
Pueraria tuberose, Plumbago zeylanica, Cinnamomum 
zeylanicum, Elettaria cardamomum, Cinnamomum tamala, 
Dioscorea bulbifera and Sesamum indicum.  
   Manix® is commonly prescribed for Nigerian males with 
low sperm count by physicians and in some cases with 
pefloxacin especially when there is UTI comorbidity. This 
research was designed to investigate the effect of this 
polyherbal formulation, Manix®, on the pharmacokinetic 
parameters of pefloxacin. 
2. Materials and methods
2.1. Drugs
   Pure sample of pefloxacin (Evans Ltd., Nigeria), MacConky 
agar (Zayo-Sigma Ltd., Nigeria), Nutrient agar (Zayo-Sigma-
Aldrich), pefloxacin tablets branded Peflacine® having 
label strength of 400 mg and Manix® were purchased from a 
registered retail pharmacy in Nsukka, Enugu State, Nigeria.
2.2. Animals 
   Ten rats of both sexes, with a mean body weight of (135.4
依9.0) g, were used in this study after being left in two 
cages (same sex to one cage) for seven days to make them 
acclimatize to the laboratory environment. The rats had 
access to food and water ad libitum. The rats’ serum samples 
were collected prior to the experiment and tested for the 
presence of antimicrobial agent using microbiological assay 
method to rule out pre-clinical antimicrobial effects of the 
animals’ feed.
2.3. Study design 
   After an overnight fasting period of 8 h on the eighth day, 
the rats were randomly devided into two groups of five rats 
per group. A group was administered pefloxacin (5.7 mg/kg) 
alone, while the other group was treated with Manix® for ten 
days and on Day 11 was dosed with pefloxacin (5.7mg/kg) 
orally.
2.4. Sample collection
   Blood samples (about 5 mL per rat per time) were collected 
from tail veins of the rats at 0 h, 0.5 h, 1 h, 4 h, 8 h and 24 h, 
after pefloxacin administration in both groups in heparinized 
containers, and being centrifuged at 3 000 r/min for 10 min. 
The serums collected were used for microbiological assay. 
2.5. Drug analysis 
   Microbiological assay was employed using clinically 
isolated E. coli samples from hospitalized patients to 
determine the serum concentrations of pefloxacin[5]. The 
nutrient agar was supplemented with 0.1% KH2PO4, then 
cooled to 50 °C and inoculated with 24-h incubated E. coli 
culture (0.1 mL/100 mL agar). After the solidification holes 
of 10 mm were punched out of the agar. Subsequently the 
punch-holes were filled with 100 µL of serum in duplicate 
for calibrators and samples. After the incubation at 37 °C 
(about 18 h), the inhibition zones were measured and the 
concentrations were calculated. 
2.6. Pharmacokinetic analysis 
   Selected pharmacokinetic parameters of pefloxacin 
alone and pefloxacin with Manix® were determined using 
WiNonlin noncompartmental programme as follows: half-
life (t1/2), apparent volume of distribution (Vd), area under 
the serum concentration-time curve (AUC0-24h), mean 
residence time (MRT) and clearance body (Cl), peak serum 
concentration (Cmax), time to reach Cmax (tmax). The relative 
bioavailability of pefloxacin after co-administration 
with Manix® was calculated by dividing the AUC after 
being combined administration by the AUC after single 
administration. Statistical analysis was performed using 
nonparametric (Mann-Whitney) two sample tests.
3. Results
   The pharmacokinetic parameters of pefloxacin when being 
administered alone and following Manix® pretreatment 
are shown in Table 1 and the concentration-time graph 
are shown in Figure 1. In the presence of Manix® the 
bioavailability parameters of pefloxacin were as follows: Cmax 
of pefloxacin (0.91依0.31) µg/mL occurred at tmax 4.0 h while 
in the group that received Manix® alongside pefloxacin Cmax 
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was (0.22依0.08) µg/mL at tmax 1.0 h respectively. The AUC of 
pefloxacin alone was (7.83依5.14) µg/h/mL while with Manix® 
was (2.60依0.08) µg/h/mL.
Table 1
The pharmacokinetic parameters of pefloxacin on co-administration 
with polyherbal formulation (Manix®) using microbiological assay.
Parameter Pef alone Pef+Manix® (E. coli)
Tmax (h) 4.0    1.0
*
Cmax (µg/mL)    0.91依0.31     0.22依0.09
*
Clast (µg/mL)    0.11依0.03   0.06依0.01
AUC (µg/h/mL)    7.83依5.14    2.60依0.08*
t1/2 (h)  10.79依1.81  13.86依4.86
*
Vd (mL)    1.10依0.01    3.51依0.80
*
Cl (mL/kg/hr)    0.07依0.01    0.18依0.02*
AUMC (µg/mL/h2)   57.65依8.89 22.67依5.04
MRT (h)    7.36依2.35   8.70依0.00
*: Significance difference between pefloxacin alone and pefloxacin 
after Manix® pretreatment at P<0.05.
Pef: Pefloxacin; Tmax: Time taken for drugs to attain maximal plasma 
concentration; Cmax: Maximal drug plasma concentration; Clast: Last 
measurable drug plasma concentration; AUC: Area under curve 
from the time of dosing to the time of the last observation; AUMC: 
Area under moment curve from the time of dosing to the time of last 
measurable concentration; MRT: Means residence time; t1/2: Terminal 
half-life: Vd: Volume of distribution based on the terminal phase; Cl: 
Total body clearance.
   This difference in Cmax, tmax and AUC between pefloxacin 
alone and pefloxacin after Manix® pre-treatment were 
significant (P<0.05). In the same way, the area under first 
moment curve (AUMC) in pefloxacin alone and after Manix® 
pretreatment were (57.65依8.89) µg/mL/h2 and (22.67依5.04) µg/
mL/h2 respectively.
   While the pharmacokinetic parameters of pefloxacin were 
as follows: half-life for pefloxacin alone and pefloxacin 
after Manix® pretreatment were (10.79依1.81) h and (13.86依
4.86) h respectively (P<0.05), the Vd of pefloxacin treated 
animal was (1.10依0.01) mL while in animals pretreated with 
Manix® the pefloxacin Vd  was (3.51依0.80) mL (P<0.05). The 
total body clearance of pefoxacin alone and pefloxacin after 
Manix® pretreatment were (0.07依0.01) mL/kg/h and (0.18依
0.02) mL/kg/h respectively.
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Figure 1. Effect of Manix® on plasma concentration of pefloxacin (Pef)
4. Discussion
   Pefloxacin has good antimicrobial spectrum against 
Gram positive and Gram negative microorganisms and has 
been successfully used in the treatment of both human 
and animal diseases. Pefloxacin is partially metabolized 
in the liver to norfloxacin, which is a potent antimicrobial 
agent[7]. Due to its favourable pharmacokinetic properties 
such as good bioavailability, better volume of distribution 
and minimal chances of resistance, it is one of the favoured 
antibacterial agents for treatment of bacterial infectious 
diseases particularly in reproductive health. 
   Bioavailability is the measurement of the rate and extent 
of systemic availability of a drug. Therefore, the AUC, the 
Cmax that indicates the amount of drug reaching the systemic 
circulation (extent) and time to reach maximal concentration 
(Tmax) that indicates time taken to reach the systemic 
circulation (rate) are used as measures for assessing 
bioavailability[10]. Manix® significantly decreased both the 
AUC and Cmax of perfloxacin and also decreased the time to 
attain Cmax of perfloxacin in the Manix® pre-treated group. 
The decreased AUC and Cmax were indicative of fewer drug 
reaching systemic circulation in the Manix® treated group 
hence reduced availability of perfloxacin. This significant 
decrease in AUC and Cmax may lead to a decrease in effective 
concentration of perfloxacin in the plasma which may 
lead to subtherapeutic level of the drug with its resultant 
treatment failure and the risk of development of microbial 
resistance. 
   Most herbs have poorly absorbable hydrocolloidal 
carbohydrates that readily bind to drugs when consumed in 
their natural powdered form[11]; Manix®, which has many 
natural product constituents, is a candidate herbal product 
likely rich in these class of carbohydrates hence was able 
to cause significant decrease in AUC and Cmax of pefloxacin 
when co-administered.
   However, the decreased AUC and Cmax may also be due to 
enhanced tissue penetration of pefloxacin in the presence of 
manix® which may limit its concentration at the plasma at 
the moment of blood withdrawal. Fluoroquinones have been 
shown to have rapid and extensive tissue distribution due to 
their hydrophilic nature and they attain high intracellular 
concentrations in macrophages and neutrophils and their 
intracellular concentrations are also shown to be 4-10 times 
greater than plasma concentrations[12]. The possible better 
intracellular concentration of the drug in the presence 
of manix® is further indicated by the significant higher 
volume of distribution value obtained in the pre-treated 
group which is also indicative of a better penetration of the 
drug into various body tissues[13].
  The reduced bioavailability of perfloxacin in the manix® 
pre-treated group may be due to activation of drug transport 
mechanism by one or more of the manix® constituents 
thus decreasing absorption and/or due to induction of drug 
metabolising enzymes leading to enhanced perfloxacin 
metabolism and subsequently decreased systemic 
availability. Perfloxacin has been shown to be metabolised 
in the liver and also bio-transformed through cytochrome 
P450 1A2 enzymes and therefore, enzyme induction by 
Manix® will lead to enhanced drug metabolism and also 
possibly enhanced the biotransformation of perfloxacin. 
These will likely result in decrease in plasma perfloxacin 
concentration in the manix® pre-treated group.
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   Meanwhile, there was significant increase in half life, 
mean resident time and clearance of perfloxacin in the 
Manix® pre-treated group which is not in line with the 
suggested possible induction of metabolising enzymes 
by Manix®. This observation may be due to the fact that 
perfloxacin is actively transformed with its principal 
metabolite being norfloxacin which is also very active 
metabolite[14]. Since microbiological assay method was used 
in this study, the effect of the norfloxacin may be involved 
in the prolongation of t1/2, Cl and MRT.
   Furthermore, the result showed a significant increase 
in the volume of perfloxacin distribution in the Manix® 
pretreated group. This may probably be due to enhanced 
effect of Manix® on the protein binding capacity of 
the drug. Pefloxacin is only 20% to 30% (<50%) protein 
bound[12]. A decrease in plasma protein binding will result 
in an increase in the volume of distribution and thus, a 
prolongation of the elimination half life and mean resident 
time. Finally, the increased clearance may be due to the 
presumed decreased effect on plasma protein binding 
leading to more drug presentation to the enzyme effect and 
hence, increased metabolism and clearance.
   A drug useful in the management of reproductive system 
infections should not have the therapeutic effectiveness 
compromised through herbal formulation co-administration. 
Our study shows that the concurrent use of Manix® and 
pefloxacin has been found to compromise the therapeutic 
effectiveness of pefloxacin thus may lead to poor clinical 
outcomes in patients. It is therefore advisable that patients 
on pefloxacin should not be placed concurrently on this 
polyherbal formulation to avoid therapy failures.   
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Background
   This is a good study in which the authors evaluated 
pharmacokinetic parameters of perfloxacin in polyherbal 
combinations therapy in a mice model. The results are good 
despite being faced with some limitations. This study could 
serve as a baseline study.
  
Research frontiers
   This study involved an evaluation of the effects of the 
commonly used polyherbal formulation on perfloxacin 
pharmacokinetic parameters. Pharmacokinetic of herbal 
concoctions is usually limited due to unknown compounds 
that not yet elucidated.
Related reports
   Some of the listed herbal plants have shown to have 
antimicrobial activity. However, antimicrobial evaluation 
technique was not mentioned here.
  
Applications
   From previous studies, it has been shown that drugs can 
antagonize each other or get synergized in combination 
therapy. However, this effect has not yet been evaluated on 
herbal concoctions without elucidated compounds despite 
the limitations or working with unknown compounds.  
Peer review
   It is a valuable study and it shows the impact of herbal 
drugs on conventional drugs when given as a combination 
therapy. This study was based on bioavailability parameters 
when given concurrently. Manix® was found to compromise 
the therapeutic effectiveness of perfloxacin.
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